Our Workstreams
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
News
- All
- News
- Press release
- All
- News
- Press release
Pfizer expands manufacturing footprint in Singapore with new state-of-the-art facility
Pfizer Inc. today announced the extension of the company’s highly automated Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park, Singapore. The official opening ...
Purpose, growth and camaraderie make up biopharma company’s formula for employee satisfaction
When he was a child, Mr Shaji Alias watched a family member struggle with asthma and saw the difference that one of GSK’s medicines made. ...
16-weeks paid leave a work-life win
Every parent of a newborn knows the toll of sleepless nights, and Mr Lam Wain Sion is no exception. However, thanks to the 16 weeks ...
BioPIPS consortium in Singapore expands membership, seeks to enhance productivity and sustainability in biologics manufacturing
The Biologics Pharma Innovation Programme Singapore (BioPIPS) consortium has been expanded with the addition of global immunotherapy company, BioNTech. The company joins global pharmaceutical companies ...
Novartis expands its biopharmaceutical manufacturing site in Singapore
Novartis today announced it broke ground for the expansion of its biopharmaceutical manufacturing plant in Singapore. The US$256 million investment will facilitate Novartis in deploying ...
AbbVie expands biologics manufacturing capacity with a $223 million investment in Singapore manufacturing site
AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This ...
Roche Singapore celebrates 50 years – a joint journey in evolving Singapore’s healthcare system
Roche today proudly commemorates its 50th anniversary of operations in Singapore. This milestone is being marked with a celebratory event attended by Mr. Ong Ye ...
GSK invests S$343 million in state-of-the-art vaccines facility expansion at Tuas Singapore
Our vaccines facility at Tuas is a key manufacturing site within our global network supplying the active ingredients used to make multiple paediatric vaccines.
BMAC Site Heads/GMs/VPs coming together to sign the BMAC Vision Zero Pledge on 17th May 2023
Seniors in Singapore can use an artificial intelligence-based technology to self-administer the screening of dementia or mild cognitive impairment. Based on their test results, general ...